May 22, 2025
Mr. Barrasso (for himself and Mr. Heinrich) introduced the following bill; which was read twice and referred to the Committee on Finance
To amend title XI of the Social Security Act to expand and clarify the exclusion for orphan drugs under the Drug Price Negotiation Program.
Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,
Section 1. Short title
This Act may be cited as the Optimizing Research Progress Hope And New Cures Act
or the ORPHAN Cures Act
.
Sec. 2. Expanding and clarifying the exclusion for orphan drugs under the Drug Price Negotiation Program
Section 1192(e) of the Social Security Act (42 U.S.C. 1320f–1(e)) is amended—
(1)
in paragraph (1), by adding at the end the following new subparagraph:
(C) Treatment of former orphan drugs
In calculating the amount of time that has elapsed with respect to the approval of a drug or licensure of a biological product under subparagraph (A)(ii) and subparagraph (B)(ii), respectively, the Secretary shall not take into account any period during which such drug or product was a drug described in paragraph (3)(A).; and
(2)
in paragraph (3)(A)—
(A)
by striking only one rare disease or condition
and inserting one or more rare diseases or conditions
; and
(B)
by striking such disease or condition
and inserting one or more rare diseases or conditions (as such term is defined in section 526(a)(2) of the Federal Food, Drug, and Cosmetic Act)
.